Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leniolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 5/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leniolisib SCHEMBL323054 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL323055 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29370516 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789521 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789551 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789594 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789520 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL15789519 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL30767853 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B | |
| Leniolisib SCHEMBL29369662 | 0.97 | PIK3CD (0.94) | PIK3CDPIK3CAPIK3CBPIK3CGHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | BRYET US, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | PIK3CD 269/4885PIK3CA 209/4885PIK3CB 188/4885 |
| US-12390420-B1 | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof | MSN, CD47, CTTN | PIK3CD 1683/4885PIK3CA 944/4885PIK3CB 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.